Effect of Rosiglitazone Treatment on Nontraditional Markers of Cardiovascular Disease in Patients With Type 2 Diabetes Mellitus

By S. Haffner, A. Greenberg, W. Weston, Hongzi Chen, K. Williams, M. Freed. Circulation, 2002

897 citations recorded by the source corpus.

Subfields: Cancer Research, Epidemiology, Molecular Biology

View Paper: https://www.semanticscholar.org/paper/54bef81344071f1a7e71bf838fb97b6e45296a2c

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cancer Research

1. Christopher K. Glass
2. S. Grundy

In Epidemiology

1. R. Kahn
2. Christopher K. Glass
3. S. Grundy
4. R. Bonow
5. J. Pickup
6. P. Calder
7. I. Tabas
8. G. Hotamisligil

In Molecular Biology

1. Christopher K. Glass
2. Bart Staels
3. Michael G. Rosenfeld
4. S. Grundy
5. P. Tontonoz

Citations in the corpus

• Inflammation and activated innate immunity in the pathogenesis of type 2 diabetes. (2004, background): “A failure to find a reduction of IL-6 accompanying the CRP reduction with glitazone treatment in some of these studies (81,84) is interesting and might indicate that statins alter the production of other cytokines involved in CRP synthesis (IL-1 and TNF- ) or inhibit the action of IL-6 at the liver ”
• Parallel SUMOylation-dependent pathways mediate gene- and signal-specific transrepression by LXRs and PPARgamma. (2007, background): “…and other cell types (Delerive et al., 1999; Glass and Ogawa, 2006; Jiang et al., 1998; Ricote et al., 1998), and this activity has been correlated with insulin-sensitizing and antiatherogenic activities of synthetic PPARg agonists (Haffner et al., 2002; Li et al., 2000; Staels and Fruchart, 2005).”
• Thiazolidinedione Use, Fluid Retention, and Congestive Heart Failure: A Consensus Statement From the American Heart Association and American Diabetes Association (2003, background): “In addition to lowering blood glucose, both drugs may benefit cardiovascular parameters, such as lipids, blood pressure, inflammatory biomarkers, endothelial function, and fibrinolytic status (6,7).”
• Overview of Nomenclature of Nuclear Receptors (2006, background): “:3) can antagonize inflammatory responses by tran-srepression of NF-(cid:2) B target genes (Haffner et al., 2002).”
• Therapeutic roles of peroxisome proliferator-activated receptor agonists. (2005, background): “01) compared with placebo; it also reduced matrix metalloproteinase-9, a useful marker of plaque stability (69).”